Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling

Abstract Introduction Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with memory, cognitive, and behavioral deficits, and brings significant economic burden on caregivers and healthcare systems. This study aims to estimate the long-term societal value of lecanemab pl...

Full description

Bibliographic Details
Main Authors: Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kang Kang, Quanwu Zhang
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Neurology and Therapy
Subjects:
Alzheimer’s disease
Cost-effectiveness
Lecanemab
CLARITY AD
Patient-level simulator
Quality-adjusted life-years
Online Access:https://doi.org/10.1007/s40120-023-00460-1

Similar Items

Similar Items